ExpreS2ion Biotechnologies – Presentation of the 2025 Full-Year Report and Q&A

You can already sign up for the event and submit your questions. You do not need to participate live in order to submit questions for the presentation.

ExpreS2ion Biotechnologies expects to publish its full-year report for 2025 (Q4) on 19 February 2026. Later the same day at 09:30, the company’s management will present the results for the financial year, provide an update on business and pipeline developments, and follow up on recent company news in a live online event, which will conclude with a Q&A session.

Since the publication of the Q3 2025 report, ExpreS2ion has reported updated immunogenicity data from the first three patients treated in the ongoing Phase I study of ES2B-C001, the company’s HER2-targeted therapeutic breast cancer vaccine. The data showed induction of HER2-specific antibody responses in multiple patients, with levels significantly above baseline, as well as early indications that the immune response may be maintained over the observation period. While the dataset remains limited and exploratory, it contributes to the biological validation of the programme. At the same time, the independent Data Safety Monitoring Board has reviewed the safety data from the first dose cohort and recommended progression to the next dose level, marking an important operational milestone in the continued clinical development.

In connection with the presentation, in addition to the review of the full-year results for 2025, focus is expected to be on the continued progress of the Phase I study, including next steps in dose escalation, anticipated clinical milestones, and the overall timeline for data generation in 2026. Investors will also have the opportunity to receive an update on the company’s capital position and financial runway, as well as the status of platform and partner projects, including ongoing vaccine programmes within malaria and other infectious diseases.

ExpreS2ion Biotechnologies is a Danish biotechnology company focused on the development of vaccines based on its proprietary ExpreS2 production platform in combination with AdaptVac’s VLP technology.

Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Corporate Visibility/Digital IR subscription agreement. Michael Friis, 10:41, 20/01-2026